Sutro Biopharma, Inc.
STRO Healthcare Biotechnology
Sutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue fell 84.6%, EPS fell 66.4% and free cash flow grew 14.6%, each against the same quarter a year earlier.
Follow STRO
Sutro Biopharma, Inc. (STRO) EV/Sales
As of 16 October 2026, Sutro Biopharma, Inc. (STRO) trades at a EV/Sales of 0.5×. Over the past ten years it has ranged from −4.5× (November 2023) to 17.3× (April 2021); the current reading is higher than 45% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.3× | — |
| FY2024 | −2.7× | — |
| FY2023 | −0.6× | — |
| FY2022 | 1.3× | (84.20%) |
| FY2021 | 8.3× | (2.77%) |
| FY2020 | 8.5× | 152.27% |
| FY2019 | 3.4× | — |
| FY2018 | −3.6× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.6× | 554.19% |
| Mar 2026 | 1.3× | — |
| Dec 2025 | −0.3× | — |
| Sep 2025 | −0.8× | — |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. compare | −35.1× |
| TRDA Entrada Therapeutics, Inc. compare | −8.3× |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. | 0.5× |
| CGEN Compugen Ltd. compare | 0.8× |
| ADCT ADC Therapeutics SA compare | 1.5× |
| ACOG Alpha Cognition Inc. compare | 9.0× |
| YARW Yarrow Bioscience, Inc compare | 124× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)